Results 201 to 210 of about 1,026,952 (386)

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Science, 2015
Marie Vetizou, J. Pitt, Romain Daillère, P. Lepage, N. Waldschmitt, C. Flament, S. Rusakiewicz, B. Routy, M. Roberti, Connie P. M. Duong, V. poirier-colame, A. Roux, S. Becharef, S. Formenti, E. Golden, Sascha Cording, G. Eberl, A. Schlitzer, F. Ginhoux, S. Mani, T. Yamazaki, N. Jacquelot, D. Enot, M. Bérard, J. Nigou, P. Opolon, A. Eggermont, P. Woerther, E. Chachaty, N. Chaput, C. Robert, C. Mateus, G. Kroemer, D. Raoult, I. Boneca, F. Carbonnel, M. Chamaillard, L. Zitvogel   +37 more
semanticscholar   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer

New England Journal of Medicine, 2018
P. Forde, J. Chaft, Kellie N. Smith, V. Anagnostou, T. Cottrell, M. Hellmann, M. Zahurak, Stephen C. Yang, David R. Jones, S. Broderick, R. Battafarano, M. Velez, N. Rekhtman, Zachary T. Olah, J. Naidoo, K. Marrone, Franco Verde, Haidan Guo, Jiajia Zhang, J. Caushi, H. Chan, John-William Sidhom, R. Scharpf, J. White, E. Gabrielson, Hao Wang, G. Rosner, V. Rusch, J. Wolchok, T. Merghoub, J. Taube, V. Velculescu, S. Topalian, J. Brahmer, D. Pardoll   +34 more
semanticscholar   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Neuromuscular Blocking Agents and Reversal Agents Usage, and Neuromuscular Blockade Monitoring in the Intensive Care Unit - Review Article. [PDF]

Int J Gen Med
Szewczyk M, Bieniecka A, Sobolewski K, Banasiak Ł, Grabarczyk Ł.   +4 more
europepmc   +1 more source

STUDIES ON STARLING'S LAW OF THE HEART. I. THE CIRCULATORY RESPONSE TO ACUTE HYPERVOLEMIA AND ITS MODIFICATION BY GANGLIONIC BLOCKADE [PDF]

, 1960
Robert L. Frye, Eugene Braunwald, Estelle Cohen   +2 more
openalex   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects. [PDF]

Front Immunol
Wang JW, Feng YF, Liu JH.
europepmc   +1 more source

Beta-adrenergic Blockade in Hypertrophic Obstructive Cardiomyopathy [PDF]

, 1966
G Cherian, Ian Brockington, Pravin M. Shah, C M Oakley, J. F. Goodwin   +4 more
openalex   +1 more source

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Science Translational Medicine, 2016
W. Zou, J. Wolchok, Lieping Chen
semanticscholar   +1 more source